chevron_leftBack
As of 13 June 2026, OptiNose, Inc. has a market cap of $97.22M USD, ranking #25768 globally and #3959 in the United States.
It ranks #2305 in the Healthcare sector, and #123 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$97.22MUSD
Enterprise Value
$151.49MUSD
Revenue (TTM)
$81.86MUSD
EBITDA (TTM)
-$15.57MUSD
Net Income (TTM)
-$29.89MUSD
EBITDA Margin
-19%
Profit Margin
-37%
PS Ratio
1.3
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Ramy Mahmoud
open_in_new
Employees
128
Founded
2010
IPO
13 Oct 2017
Website
optinose.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | 1.9% | 4.7% | 60% | 74% | -47% |
News
Loading...
OPTN Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
OPTN
OptiNose Inc
ISIN: US68404V2097
Shares Out.:
Shares Outstanding:
10.127M1
Shares Float:
7.906M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
9.60 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: RVMD
|
$29.56B
30K%
|
-
|
|
LSE: INDV
|
$2.07B
2K%
1.54B GBP
|
-
|
|
OTCMKTS: NDOI
|
$1.8B
2K%
|
0.4
|
|
NASDAQ: DVAX
|
$1.76B
2K%
|
-
|
|
NASDAQ: AVBP
|
$1.33B
1K%
|
-
|
|
NYSE: BRBR
|
$1.02B
954%
|
12.1
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TLV: TEVA
|
$36.75B
38K%
108.92B ILS
|
24.2
|
|
SHE: 002001
|
$15.84B
16K%
107.34B CNY
|
16.0
|
|
NSE: CIPLA
|
$11.16B
11K%
1.06T INR
|
23.4
|
|
NSE: LUPIN
|
$11.04B
11K%
1.05T INR
|
22.7
|
|
SHE: 002653
|
$9.09B
9K%
61.6B CNY
|
80.6
|
|
EPA: ABVX
|
$8.74B
9K%
7.57B EUR
|
-
|
chevron_leftBack